Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool November 11, 2008 Brian Orelli	AOB Is A-OK Growing through acquisitions seems to be working.
The Motley Fool February 26, 2009 Brian Orelli	Big Blue Struts Its Stimulus Stuff The company announces that it had signed up four hospital groups in the U.S. to use its electronic medical records systems, after the stimulus bill contained $19 billion in grants and incentives to encourage doctors and hospitals to invest in electronic medical records.
The Motley Fool March 10, 2009 Brian Orelli	So Much Potential, So Little Growth In its quest to become the Johnson & Johnson of China, this purveyor of traditional Chinese medicine has been growing through acquisitions, but has paid for them through dilutive stock offerings.
The Motley Fool August 10, 2009 Brian Orelli	This Volatile Stock Has Growth Potential China is scary. AOB? Scarier.
The Motley Fool April 22, 2009 Selena Maranjian	Will Health-Care Reform Hurt Investors? The bad news here is that there's quite a bit of uncertainty around this issue, and that some health-care-focused companies may end up suffering. Read on to see who.
The Motley Fool September 30, 2009 Dave Mock	Health-Care Stocks Obama Would Buy This up-and-coming sector could play a big role in reform, especially for companies that bring new efficiencies to health care.
The Motley Fool December 9, 2009 Brian Orelli	Welcome to Club Biogeneric, Pfizer! The megadrugmaker jumps on the biogeneric bandwagon.
The Motley Fool December 27, 2007 Brian Orelli	Drugmaker Growth: The China Connection Just like other industries, the pharmaceutical industry has realized that China is a good place to find cheap labor. While reluctant to set up FDA-regulated manufacturing plants in China, other stages of drug development can be done there.
The Motley Fool August 27, 2009 Brian Orelli	The List You Have to Be On Good for you if your company's products made the cut in China. This sounds like a growth opportunity for American Oriental Bioengineering and anyone else who can get a place on the list.
The Motley Fool June 11, 2009 Brian Orelli	The FTC Hates You, Too The agency weighs in (unhappily) on follow-on biologics.
The Motley Fool January 20, 2009 Brian Orelli	Johnson & Johnson Nimble ... for Now The health-care giant reports increasing earnings, despite falling revenue.
The Motley Fool August 24, 2010 Brian Orelli	One Day, the J&J Recalls Will End Just not today. Johnson & Johnson's consumer health segment gets more than half of its sales from outside the U.S., so tainting its image outside the U.S. could be costly as well.
The Motley Fool May 21, 2009 Selena Maranjian	Make Money With or Without Health-Care Reform While there's obviously a lot at stake in the health-care discussions going on in Washington, you don't have to guess right about what's going to happen in order to profit from the industry.
The Motley Fool June 10, 2008 Brian Lawler	Buy Back Shares, Then Issue More? Investors marvel at what seems like temporary financial schizophrenia from American Oriental Bioengineering.
The Motley Fool September 5, 2008 Brian Orelli	Mindray Medical Zaps Ahead Revenue almost doubled as the company recorded two months of sales from Datascope's patient-monitoring business, which it acquired in the beginning of May.
The Motley Fool October 14, 2009 Brian Orelli	Consistency Makes This Stock a Winner Abbott turns in a solid quarter, but it needs to keep branching out.
The Motley Fool November 8, 2011 Brian Wilson	2 Health-Care Stocks for Times of Uncertainty Just because Abbott and Johnson & Johnson don't undertake as much risk as other health-care giants doesn't mean that shareholders won't see impressive growth in revenues.
The Motley Fool June 4, 2010 Brian Orelli	Out With Drugs, in With Medical Devices Johnson & Johnson's movement in medical devices and diagnostics is headed in the right direction, but whether Johnson & Johnson is a buy depends a lot on how it handles its current drug problem. Unfortunately investors can't have one without the other.
The Motley Fool October 20, 2011 Brian Orelli	Mini J&J? I Guess Not Abbott says it plans to split in two: drugs in one company, everything else in the other.
The Motley Fool January 17, 2012 Brian Orelli	Pharma Focus Is Good For Your Portfolio Build your own portfolio.
The Motley Fool August 4, 2009 Tim Beyers	Does the President Want You to Buy This Stock? Which company is likeliest to produce the innovation of which the president spoke recently? Take a look at why IBM may be the stock for the future.
The Motley Fool December 18, 2009 Brian Orelli	2009: The Year Pharma Learned to Love Itself While anything is possible, don't expect too much more consolidation of major drugmakers in 2010 and beyond.
The Motley Fool April 15, 2009 Brian Orelli	Johnson & Johnson Still Withstands Recession While Johnson & Johnson is big, it has proven to be agile during the recession, and this quarter was no different.
The Motley Fool June 5, 2007 Brian Lawler	Another Buyout in the Works for AOB? The Chinese health-care nutritional supplement provider announces a very large debt offering. Investors, take note.
BusinessWeek March 4, 2010 Frederik Balfour	The Ka-Ching in China Luring Medical Giants GE, Siemens, and others are angling for a piece of the $125 billion Beijing plans to spend on health care.
The Motley Fool October 3, 2007 Jack Uldrich	IBM Will Now See Your Avatar IBM is creating a 3-D representation of patients in the form of an avatar, on which all their digital health-care information can be quickly and easily displayed and, thus, accessed by a doctor. Investors, take note.
The Motley Fool January 23, 2007 Seth Jayson	'Tis the Season Chinese medical device maker Mindray Medical $309 million offering looks to be all insider selling. Investors, take note.
The Motley Fool February 12, 2009 Brian Orelli	Stimulus Could Be Bitter Pill for Some Investors Health-care shareholders need to watch provisions of the stimulus bill closely.
The Motley Fool March 24, 2009 Robert Steyer	Drugmakers Diversify -- Again Merck and Pfizer choose businesses they once eschewed.
The Motley Fool January 12, 2009 Brian Orelli	Trust Management or Don't Buy American Oriental Bioengineering, purveyor of traditional Chinese medical products, bought a $70 million building to use as a "Convention and Training Center," and investors aren't happy about it.
The Motley Fool January 15, 2009 Tim Hanson	One Heckuva Cheap Stock Would you pay nine times earnings to buy shares of a company growing 48% annually? What about six times earnings for a company growing by 50%? How about six times for a company growing at greater than 80% per year? Take a look at three such Chinese stocks.
The Motley Fool April 19, 2005 Nathan Slaughter	Diagnosis: JNJ A-OK The health-care conglomerate beats expectations on strong international results.
The Motley Fool August 26, 2010 Rich Smith	This Just In: Upgrades and Downgrades Deutsche Securities took the bull side of Wall Street's bearish, anti-medical devices trade, initiating coverage of diagnostic equipment maker China Medical Technologies and reinitiating coverage of Mindray Medical, both with buys.
The Motley Fool October 19, 2005 Stephen D. Simpson	Abbott Still a Little Pale Perhaps drug and device pipelines, plus margin improvements, can put some color back into the diversified health-care company's stock.
The Motley Fool November 7, 2008 Brian Orelli	Will Obama Make Your Portfolio Healthy? The changes coming in the health-care industry could be a mixed bag of good and bad for your portfolio.
The Motley Fool December 1, 2008 Brian Orelli	Johnson & Johnson Firms Things Up The health-care giant acquires breast-implant maker Mentor.
The Motley Fool August 27, 2010 Brian Orelli	A Recall a Week, That's All We Ask For Johnson & Johnson, apparently that's too much.
The Motley Fool January 23, 2007 Ralph Casale	Win-Win for Abbott and GE? Abbott trades its medical diagnostics segment for cold hard cash. Will shareholders see this deal as a win-win scenario? Investors, take note.
The Motley Fool July 14, 2008 Brian Orelli	Foolish Forecast: J&J Trudges Along In advance of earnings analysts wonder if Johnson & Johnson is a recovery story waiting to happen, or still stuck in a rut?
The Motley Fool January 26, 2007 Jack Uldrich	Big Blue Will See You Now A new medical-records search engine could streamline medical services and improve patient health. This system is just one more reason IBM makes a great blue chip investment.
The Motley Fool February 27, 2009 Brian Orelli	Can $634 Billion Save the U.S. Health Care System? The good news is that Obama's budget includes a $634 billion down payment on getting insurance for the 48 million uninsured. The bad news is that the president has to pay for that by cutting costs in other areas.
The Motley Fool October 27, 2011 Alexander Crawford	Medical Devices: Venture Capitalists Lobby to Change FDA Approval Process Do you think these firms stand to benefit from new regulations?
The Motley Fool February 10, 2009 Mike Pienciak	China 2009: Continued Risk, Ongoing Opportunity Investing in China still looks dicey, but there are safe havens.
The Motley Fool July 6, 2009 Nathan Parmelee	China's Getting Old Fast According to an article in last week's The Economist, which references United Nations data on aging trends, China can expect to see an ever-greater portion of retirees dominate its population. And health-care spending should soar.
The Motley Fool March 3, 2009 Brian Orelli	Stop Worrying About Follow-On Biologics They're inevitable, but they won't hurt biotech as much as you might think.
The Motley Fool October 26, 2007 Brian Orelli	Investing in Follow-On Biologics Investors, while approvals of follow-on biologics in the U.S. are probably still years away, now is the time to do your research. Those that are leading the race overseas are likely to be first in line when the FDA opens its door to applications.
The Motley Fool February 26, 2010 Brian Orelli	Political Theater: More Entertaining Than Helpful Health-care reform, like health-care stocks, remains still stuck in limbo.
The Motley Fool April 7, 2008 Mac Greer	Fool Video: 3 Stocks Ready to Rock, Apple's Sweet Music, and China's Investing Remedy Will the music last for Apple's iTunes, or will Microsoft's Zune finally find its rhythm? Is American Oriental Bioengineering the right medicine for investors? These questions and others are discussed in this video.
The Motley Fool May 12, 2009 Brian Orelli	Your Company Is Giving Away Revenue Bad news for investors in the health-care industry: the companies you invest in just pledged to give back 1.5% of their expected U.S. revenue growth to President Obama.
The Motley Fool January 25, 2011 Eric Dutram	Tuesday's ETF to Watch: iShares Dow Jones U.S. Health Care Index Fund (IYH) The health-care sector has stagnated in recent weeks -- what does that mean for these ETFs?